Here’s a new buy for 2018

Article Excerpt

BECTON DICKINSON & CO. $219 (New York symbol BDX; Conservative Growth Portfolio; Consumer sector; Shares outstanding: 266.2 million; Market cap: $58.3 billion; Price-tosales ratio: 4.8; Dividend yield: 1.4%; TSINetwork Rating: Above Average; www.bd.com) has now completed its $25 billion takeover of C.R. Bard Inc. (old New York symbol BCR). Under the terms of the deal, Bard investors received $222.93 in cash plus 0.5077 of a Becton share for each BCR share they held. We first recommended Bard in our April 2002 issue. Based on its closing price just before the takeover, it gained 1,062.2% for us. Bard’s stents, catheters and surgical tools nicely complement Becton’s needles, syringes and disease testing products. The combined company will have annual revenue of $16 billion. The acquisition pushed up Becton’s longterm debt to $22.1 billion as of December 31, 2017. That’s a high, but manageable 38% of its market cap. Moreover, the merger will let Becton cut $300 million from its annual costs over the next three years. The…